|
WO2020139803A1
|
|
Benzothiadiazine derivatives and compositions comprising the same for treating disorders mediated by adenosine
|
|
WO2020139334A2
|
|
Multiplex quantitative method for microrna
|
|
US2018214426A1
|
|
Pyrazolo[4,3-c]quinoline derivatives for inhibition of beta-glucuronidase
|
|
US2018037888A1
|
|
Short interfering RNA for treating cancer
|
|
AU2014415566A1
|
|
Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
|
|
WO2015077685A1
|
|
Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits
|
|
US2016185875A1
|
|
Antibody locker for the inactivation of protein drug
|
|
US2015374741A1
|
|
Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
|
|
WO2014127232A2
|
|
Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
|
|
SG11201407729VA
|
|
Methods for drug screen using zebrafish model and the compounds screened thereform
|
|
AU2012308243A1
|
|
Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
|
|
WO2013040428A1
|
|
Microfluidic chips for acquiring sperms with high motility, productions and applications thereof
|
|
AU2012301937A1
|
|
Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
|
|
WO2012145676A1
|
|
Polypeptides and bacteriophages specific to klebsiella pneumoniae capsular type strains
|
|
WO2012040218A1
|
|
Recombinant flaviviral constructs and uses thereof
|
|
CN102858370A
|
|
Polysaccharide conjugation with detoxified E. COLI heat labile enterotoxin (LT) used as vaccine
|
|
BR112012015827A2
|
|
new pyrimidine compounds as inhibitors of mtor and p13k
|
|
CA2782796A1
|
|
Compositions and methods for the treatment of angiogenesis-related eye diseases
|
|
WO2011069149A2
|
|
Cathepsin s inhibitors
|
|
WO2010075101A2
|
|
Treating picornavirus infection by targeting microrna mir-141
|
